Skip to content

US · AUTL · BIOTECHNOLOGY

Autolus Therapeutics plc (AUTL) intrinsic value and stock valuation

$0.91as of 2026-11-21 · Mkt cap 561.56M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Autolus Therapeutics plc DCF and intrinsic value

InvestorsCraft values AUTL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AUTL’s statements →

Autolus Therapeutics plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology London, GL W12 7FP autolus.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$75.6M+113.1% 5y CAGRd
20152025
Net income
-$-288.2M
20152025
Free cash flow
-$-310.7M
20152025
Total equity
$178.1M-3.2% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$75.6M$10.1M$1.7M$6.19M$1.51M
Operating income-$-281.44M-$-241.43M-$-179.7M-$-142.89M-$-140.37M
Net income-$-288.2M-$-220.66M-$-208.38M-$-148.84M-$-142.1M
EPSd-$-1.08M-$-864.79K-$-1.2M-$-1.57M-$-1.97M
Operating cash flow-$-283.57M-$-206.27M-$-145.59M-$-112.31M-$-117.86M
Capital expenditure-$-27.13M-$-34.82M-$-10.99M-$-10.84M-$-8.86M
Free cash flow-$-310.7M-$-241.09M-$-156.57M-$-123.15M-$-126.72M
Total assets$589.1M$782.7M$375.4M$490.3M$405.6M
Total debt$351.6M$52.6M$53M$24.3M$68M
Net debt$247.5M-$-174.75M-$-186.6M-$-358.18M-$-242.32M
Total equity$178.1M$427.3M$111.5M$298.7M$313.3M
Cash and short-term investments$300.7M$588M$239.6M$382.4M$310.3M
Income statement
20252024202320222021
Revenue$75.6M$10.1M$1.7M$6.19M$1.51M
Cost of revenue$96.6M$141M$0.00$0.00$0.00
Gross profit-$-21.03M-$-130.9M$1.7M$6.19M$1.51M
Research and development expenses$128.6M$158.1M$130.5M$117.4M$110.8M
Selling, general and administrative expenses$131.8M$0.00$46.7M$31.9M$31.9M
Other expenses$0.00-$-47.61M$4.17M-$-170K-$-820K
Operating expenses$260.4M$110.5M$181.4M$149.1M$141.9M
Cost and expenses$357M$251.6M$181.4M$149.1M$141.9M
Interest income$19M$32.4M$13.5M$1.71M$260K
Interest expense$36.8M$9.29M$45.1M$8.9M$1.1M
Depreciation and amortization$9.84M$7.72M$6.57M$7.42M$8.46M
Ebitda-$-250.26M-$-233.07M-$-156.77M-$-132.24M-$-132.47M
Operating income-$-281.44M-$-241.43M-$-179.7M-$-142.89M-$-140.37M
Total other income/expenses, net-$-15.41M$22.3M-$-28.7M-$-5.67M-$-1.66M
Income before tax-$-296.85M-$-219.13M-$-208.4M-$-148.57M-$-142.04M
Income tax expense-$-8.65M$1.53M-$-20K$270K$60K
Net income-$-288.2M-$-220.66M-$-208.38M-$-148.84M-$-142.1M
Weighted average shares outstanding$266.1M$255.2M$173.9M$95M$72.1M
Weighted average diluted shares outstanding$266.1M$255.2M$173.9M$95M$72.1M
Balance sheet
20252024202320222021
Cash and short-term investments$300.7M$588M$239.6M$382.4M$310.3M
Net receivables$75.8M$48.2M$1.05M$29M$70K
Inventory$33.2M$4.14M$0.00$0.00$0.00
Total current assets$435.9M$660.9M$275.3M$425.8M$347M
Property, plant and equipment, net$128.5M$105.1M$95.7M$58.4M$52.3M
Goodwill and intangible assets$19.8M$12.4M$0.00$0.00$70K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$153.2M$121.8M$100.1M$64.5M$58.6M
Total assets$589.1M$782.7M$375.4M$490.3M$405.6M
Accounts payable$3.08M$1.97M$100K$530K$430K
Short-term debt$14.6M$3M$5.05M$5.04M$4.45M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$73.4M$60.7M$44.7M$46.4M$28.6M
Long-term debt$337M$49.6M$47.9M$19.2M$63.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$337.5M$294.7M$219.2M$145.2M$63.7M
Capital lease obligations$66.8M$52.6M$53M$24.3M$21M
Total liabilities$410.9M$355.4M$263.9M$191.6M$92.2M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-1.39B-$-1.1B-$-878.56M-$-670.18M-$-521.34M
Accumulated other comprehensive income (loss)-$-5.36M-$-29.17M-$-28.99M-$-38.9M-$-8.45M
Total equity$178.1M$427.3M$111.5M$298.7M$313.3M
Total investments$196.6M$360.6M$0.00$0.00$0.00
Total debt$351.6M$52.6M$53M$24.3M$68M
Net debt$247.5M-$-174.75M-$-186.6M-$-358.18M-$-242.32M
Cash flow statement
20252024202320222021
Net income-$-287.53M-$-220.66M-$-208.38M-$-148.84M-$-142.1M
Depreciation and amortization$9.81M$7.72M$6.57M$7.42M$8.46M
Stock-based compensation$14.4M$15.5M$11.2M$12M$9.94M
Change in working capital-$-52.11M-$-23.66M$290K$3.97M$4.14M
Accounts receivable-$-24.21M$0.00$0.00$0.00$0.00
Inventory-$-40.34M-$-4.23M$0.00$0.00$0.00
Accounts payable$1.3M$1.59M-$-510K$20K-$-1.82M
Net cash provided by operating activities-$-283.57M-$-206.27M-$-145.59M-$-112.31M-$-117.86M
Investments in property, plant and equipment-$-19.04M-$-22.07M-$-10.99M-$-10.84M-$-8.86M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$158.5M-$-394.55M-$-10.99M-$-10.84M-$-8.86M
Common stock issued$0.00$550M$0.00$163.9M$245.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-4.34M$589.6M-$-880K$223.6M$284.1M
Net change in cash-$-123.17M-$-11.53M-$-142.43M$72.1M$156.6M
Cash at end of period$105.6M$228.8M$240.3M$382.8M$310.7M
Operating cash flow-$-283.57M-$-206.27M-$-145.59M-$-112.31M-$-117.86M
Capital expenditure-$-27.13M-$-34.82M-$-10.99M-$-10.84M-$-8.86M
Free cash flow-$-310.7M-$-241.09M-$-156.57M-$-123.15M-$-126.72M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Autolus Therapeutics plc

        Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.

        CEO
        Christian Martin Itin
        Employees
        752
        Beta
        2.03

        Explore

        Frequently asked questions

        What is the intrinsic value of Autolus Therapeutics plc (AUTL)?

        InvestorsCraft does not currently publish an intrinsic value for AUTL. How the IC value is calculated.

        Is AUTL undervalued?

        InvestorsCraft does not publish an undervaluation signal for AUTL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.